---
title: "Predictors of Healthcare Costs for Commercially Insured Adults with Tuberculosis in the US (2013–2"
id: "medrxiv-0-predictors-of-healthcare-costs-among-commercially-insured-persons-with"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-0-predictors-of-healthcare-costs-among-commercially-insured-persons-with"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.25.26361351v1?rss=1"
published_at: "2026-08-27T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Predictors of Healthcare Costs for Commercially Insured Adults with Tuberculosis in the US (2013–2
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-0-predictors-of-healthcare-costs-among-commercially-insured-persons-with
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.25.26361351v1?rss=1)
- **Published At:** 2026-08-27T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Retrospective cohort study using the Merative MarketScan Commercial Claims Database (2013–2018) examined 12-month all-cause healthcare costs among commercially insured adults diagnosed with **tuberculosis**. - Sample included 303 adults (median age 46 years; 52% male). - Comorbidities in the cohort included HIV (5%), hepatitis B (4%), and drug use disorder (4%); Charlson comorbidity score was used to quantify burden. - Mean total 12-month all-cause costs were $32,404 (median $8,075; SD $78,829). - Median costs were significantly higher for persons with any specified comorbidity versus those without ($11,930 vs $3,385; p<0.001). - Independent predictors of higher 12-month costs were **HIV coinfection** (adjusted cost ratio [aCR] 4.70, p<.001) and **drug use disorder** (aCR 2.62, p=.03). - Pharmacy expenditures largely drove the cost increase associated with HIV (pharmacy aCR 16.4). - Comorbidity burden measured by Charlson score was a continuous independent predictor of cost (aCR 1.36 per Charlson point, p<.001). - Authors conclude that costs for TB care among commercially insured persons are substantial and further increased by comorbidities; improved screening, care coordination, and management of TB and high-risk comorbidities could reduce costs. - Study used de-identified licensed claims data and was deemed exempt from UCSF IRB review; data access restrictions apply.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=sIxIT8nT9AKTMW0r8cCltNDFgbJLiQdwht99ppxhT1o-1787881489.1513224-1.2.1.1-KWwlsaqJWeLdEa_OP148vadF7Rn4YslCmb9hjqj_gbs6.Nk.x92dyOpq.kcwd0sm) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.25.26361351v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Predictors of Healthcare Costs among Commercially-Insured Persons with Tuberculosis in the United States, 2013 to 2018 [ View ORCID Profile](http://orcid.org/0000-0002-8555-5667)Devan Jaganath, [ View ORCID Profile](http://orcid.org/0000-0002-1844-1993)Vinith Ilavarasan, [ View ORCID Profile](http://orcid.org/0000-0002-8923-2806)Robert Wong, [ View ORCID Profile](http://orcid.org/0009-0007-3934-3974)Amit Chitnis, [ View ORCID Profile](http://orcid.org/0000-0001-7567-7727)Matthew T Murrill doi: https://doi.org/10.64898/2026.08.25.26361351 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Devan Jaganath 1 University of California, San Francisco; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Devan%2BJaganath%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Jaganath%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADevan%2BJaganath%2B) * [ORCID record for Devan Jaganath](http://orcid.org/0000-0002-8555-5667 "Open in new tab") * For correspondence: devan.jaganath@ucsf.edu Vinith Ilavarasan 2 UC Berkeley School of Public Health; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Vinith%2BIlavarasan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ilavarasan%20V&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AVinith%2BIlavarasan%2B) * [ORCID record for Vinith Ilavarasan](http://orcid.org/0000-0002-1844-1993 "Open in new tab") Robert Wong 3 Stanford University School of Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Robert%2BWong%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Wong%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARobert%2BWong%2B) * [ORCID record for Robert Wong](http://orcid.org/0000-0002-8923-2806 "Open in new tab") Amit Chitnis 4 Public Health Department of Alameda County * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Amit%2BChitnis%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Chitnis%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAmit%2BChitnis%2B) * [ORCID record for Amit Chitnis](http://orcid.org/0009-0007-3934-3974 "Open in new tab") Matthew T Murrill 1 University of California, San Francisco; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Matthew%2BT%2BMurrill%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Murrill%20MT&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMatthew%2BT%2BMurrill%2B) * [ORCID record for Matthew T Murrill](http://orcid.org/0000-0001-7567-7727 "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.25.26361351v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1287486/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.25.26361351v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1287486/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.25.26361351v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1287486/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.08.25.26361351v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1287486/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.25.26361351v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1287486/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.25.26361351v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1287486/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Context: Most individuals in the United States have commercial health insurance, yet costs for tuberculosis (TB) care have focused on the public sector. Objective: To quantify 12 month all cause healthcare costs and identify predictors of expenditure among commercially insured persons with TB disease in the United States. Design/Setting: Retrospective cohort study using Merative (TM) MarketScan (R) Commercial Claims Database (2013 to 2018). Participants: Adults 18 years old with TB disease Main Outcome Measure: Total 12 month all cause healthcare costs (outpatient, inpatient, pharmacy) were calculated from the date of diagnosis. Adjusted cost ratios (aCR) were estimated using a Gamma generalized linear model. Results: We included 303 individuals diagnosed with TB disease, median age 46 years, 158 (52%) male, 16 (5%) with HIV, 12 (4%) with hepatitis B (HBV), and 13 (4%) with a drug use disorder. Mean total 12-month costs were $32,404 (median $8,075; SD $78,829). Median 12-month costs were substantially higher among persons with any comorbidity (HIV, HBV, hepatitis C (HCV), alcohol use disorder, drug use disorder, or Charlson score >0) compared to those without ($11,930 [IQR $4,194 to $36,073] vs $3,385 [IQR $1,506 to $8,609]; p The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.25.26361351v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.21.26360249v1 "A Framework For Large-Scale Reconstruction Of Extended Pedigrees To Facilitate Gene Discovery In ALS")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.24.26361254v1 "A versioned, analysis-ready archive of United States State Cancer Profiles county- and state-level estimates") Posted August 27, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.25.26361351v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/27/2026.08.25.26361351.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.25.26361351v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.08.25.26361351v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/27/2026.08.25.26361351.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Predictors of Healthcare Costs among Commercially-Insured Persons with Tuberculosis in the United States, 2013 to 2018 Devan Jaganath, Vinith Ilavarasan, Robert Wong, Amit Chitnis, Matthew T Murrill medRxiv 2026.08.25.26361351; doi: https://doi.org/10.64898/2026.08.25.26361351 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.25.26361351v1%26text%3DPredictors%2520of%2520Healthcare%2520Costs%2520among%2520Commercially-Insured%2520Persons%2520with%2520Tuberculosis%2520in%2520the%2520United%2520States%252C%25202013%2520to%25202018 "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.25.26361351v1%26t%3DPredictors%2520of%2520Healthcare%2520Costs%2520among%2520Commercially-Insured%2520Persons%2520with%2520Tuberculosis%2520in%2520the%2520United%2520States%252C%25202013%2520to%25202018 "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.25.26361351v1%26title%3DPredictors%2520of%2520Healthcare%2520Costs%2520among%2520Commercially-Insured%2520Persons%2520with%2520Tuberculosis%2520in%2520the%2520United%2520States%252C%25202013%2520to%25202018%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.25.26361351v1%26title%3DPredictors%2520of%2520Healthcare%2520Costs%2520among%2520Commercially-Insured%2520Persons%2520with%2520Tuberculosis%2520in%2520the%2520United%2520States%252C%25202013%2520to%25202018 "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.25.26361351) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.25.26361351v1&count=horizontal&via=&text=Predictors%20of%20Healthcare%20Costs%20among%20Commercially-Insured%20Persons%20with%20Tuberculosis%20in%20the%20United%20States%2C%202013%20to%202018&counturl=www.medrxiv.org/content/10.64898/2026.08.25.26361351v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (612) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (892) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (325) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4753) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (474) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (406) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (640) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1610) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15803) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1194) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6969) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (726) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1051) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4959) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1422) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1731) * [Hematology](https://www.medrxiv.org/collection/hematology) (578) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1329) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16227) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1158) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (661) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (150) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (718) * [Neurology](https://www.medrxiv.org/collection/neurology) (7161) * [Nursing](https://www.medrxiv.org/collection/nursing) (360) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1072) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1226) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (998) * [Oncology](https://www.medrxiv.org/collection/oncology) (3563) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1032) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (392) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (445) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (464) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (139) * [Pathology](https://www.medrxiv.org/collection/pathology) (702) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1770) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (730) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (758) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5813) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9665) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2371) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1428) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1236) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (632) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (762) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (572) * [Surgery](https://www.medrxiv.org/collection/surgery) (762) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (106) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (301) * [Urology](https://www.medrxiv.org/collection/urology) (285) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All commen
## Related Clinical Research

- [Mortality and Predictors Among People Living with HIV Newly Enrolled in Care at Bamenda Regional H](https://medichelpline.com/clinical-feed/medrxiv-11-mortality-and-associated-factors-among-people-living-with-hiv-newly-initiated.md)
- [Case report: ADMIO type 1 linked to de novo STAT3 gain-of-function mutation](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-a-case-report-of-admio-type-1-caused-by-a-de-novo-stat3-gain-of-function.md)
- [District-level HIV and TB vulnerability to climate hazards in South Africa: a composite index anal](https://medichelpline.com/clinical-feed/medrxiv-4-district-level-hiv-and-tb-health-system-vulnerability-to-climate-and-weather.md)
- [Determinants of Favorable MDR-TB Treatment Outcomes in Zambia, 2018–2022](https://medichelpline.com/clinical-feed/plos-one-16-determinants-of-favorable-treatment-outcomes-in-multidrug-resistant.md)
- [MMR vaccines: separating measles, mumps, rubella shots — myths and facts](https://medichelpline.com/clinical-feed/medical-news-today-0-should-the-measles-mumps-rubella-vaccines-be-separate-myths-vs-facts.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.